Evidence that new antihypertensives are superior to older drugs

Lancet

Volumn 366, Issue 9489, 2005, Pages 869-871

  Staessen, Jan A ^a   Birkenhäger, Willem H ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ATENOLOL; BENDROFLUMETHIAZIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXAZOSIN; LISINOPRIL; PERINDOPRIL;

CARDIOVASCULAR RISK; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG INDUSTRY; GOVERNMENT; HAZARD ASSESSMENT; HEALTH INSURANCE; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERTENSION; MEDICAL RESEARCH; MORTALITY; NOTE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SENSITIVITY ANALYSIS; STATISTICAL SIGNIFICANCE;

EID: 24644498646     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(05)67147-4     Document Type: Note

References (18)

1. JA Staessen, Y Li, L Thijs, JG Wang Blood pressure reduction and cardiovascular prevention: an update including the 2003-2004 secondary prevention trials Hypertens Res 28 2005 385 407
2. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) JAMA 288 2002 2981 2997
3. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group Diuretic versus α-blocker as first step antihypertensive therapy: final results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Hypertension 42 2003 239 246
4. B Dahlöf, PS Sever, NR Poulter for the ASCOT investigators Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial Lancet 2005 DOI:10.1016/S0140-6736(05)67185-1
5. JA Staessen, JG Wang, L Thijs Cardiovascular prevention and blood pressure reduction: a meta-analysis Lancet 358 2001 1305 1315
6. JA Staessen, JG Wang, L Thijs Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003 J Hypertens 21 2003 1055 1076
7. Blood Pressure Lowering Treatment Trialists' Collaboration Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials Lancet 362 2003 1527 1535
8. PS Sever, B Dahlöf, NR Poulter for the ASCOT investigators Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOTT - LLA): a multicentre randomised controlled trial Lancet 361 2003 1149 1158
9. NR Poulter, H Wedel, B Dahlöf for the ASCOT investigators Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA) Lancet 2005 DOI:10.1016/S0140-6736(05)67186-3
10. JA Staessen, L Thijs, WH Birkenhäger VALUE: analysis of results Lancet 364 2004 931
11. P Verdecchia, G Reboldi, A Angeli Angiotensin-converting enzyme inhibitors and calcium channel blockers for coronary heart disease and stroke prevention Hypertension 46 2005 386 392
12. MJ Brown, CR Palmer, A Castaigne Morbidity and mortality in patients randomised to double-blind treatment with long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS Study: intervention as a goal in hypertensive treatment (INSIGHT) Lancet 356 2000 366 372
13. The PEACE Trial Investigators Angiotensin-converting-enzyme inhibition in stable coronary heart artery disease N Engl J Med 351 2004 2058 2068
14. S Julius, SE Kjeldsen, M Weber for the VALUE trial group Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial Lancet 363 2004 2022 2031
15. PS Sever, B Dahlöf, NR Poulter Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial J Hypertens 19 2001 1139 1147
16. P Verdecchia, G Reboldi, F Angeli Adverse prognostic significance of new diabetes in treated hypertensive subjects Hypertension 43 2005 963 969
17. European Society of Hypertension/European Society of Cardiology Guidelines Committee 2003 European Society of Hypertension/European Society of Cardiology guidelines for the management of arterial hypertension J Hypertens 21 2003 1011 1053
18. JA Staessen, L Thijs, R Fagard for the Systolic Hypertension in Europe (Syst-Eur) Trial Investigators Effects of immediate versus delayed antihypertensive therapy on outcome in the Systolic Hypertension in Europe Trial J Hypertens 22 2004 847 857